Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
40 rows where has_known_aptamer = 1, surface_class = "A2_pm_peripheral" and tier = "Tier 1.5" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: pdb_count_total, aptamer_count_pubmed, opentargets_top_disease_name
tier 1
- Tier 1.5 · 40 ✖
surface_class 1
- A2_pm_peripheral · 40 ✖
has_known_aptamer 1
- 1 · 40 ✖
has_activation_state_pdb_pair 1
- 0 40
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| O60315 | ZEB2 | Zinc finger E-box-binding homeobox 2 | Tier 1.5 | 0.789 | 1 | A2_pm_peripheral | 1 | 48.16 | 0 | 0 | 1 | 3 | 27719642, 24146916, 18698484 | 1 | Mowat-Wilson syndrome | 0.8313744323041312 | ||
| P11274 | BCR | Breakpoint cluster region protein | Tier 1.5 | 0.785 | 1 | A2_pm_peripheral | 5 | 64.81 | 0 | 0 | 1 | 20 | 41951939, 41535871, 40882628, 37937247, 37103734, 32929022, 32507237, 31825964, 31650445, 31295447, 29299123, 28686804, 25809097, 23836560, 22411871, 21810089, 21653319, 21030439, 16990253, 11713794 | 1 | chronic myelogenous leukemia | 0.8183048540102864 | ||
| Q9ULC3 | RAB23 | Ras-related protein Rab-23 | Tier 1.5 | 0.776 | 1 | A2_pm_peripheral | 6 | 79.56 | 1 | 0 | 1 | 1 | 23618401 | 1 | RAB23-related Carpenter syndrome | 0.7879955689930709 | ||
| P55263 | ADK | Adenosine kinase | Tier 1.5 | 0.769 | 1 | A2_pm_peripheral | 4 | 93.31 | 0 | 0 | 1 | 2 | 26051465 | 1 | adenosine kinase deficiency | 0.7617058236708037 | ||
| P35241 | RDX | Radixin | Tier 1.5 | 0.749 | 1 | A2_pm_peripheral | 2 | 86.56 | 0 | 0 | 1 | 2 | 33253235, 30700648 | 1 | hearing loss, autosomal recessive | 0.6973070672344621 | ||
| P32121 | ARRB2 | Beta-arrestin-2 | Tier 1.5 | 0.719 | 1 | A2_pm_peripheral | 1 | 83.81 | 1 | 0 | 1 | 4 | 24736311, 40652239, 29054528 | 1 | cancer | 0.5962458729823639 | ||
| P09769 | FGR | Tyrosine-protein kinase Fgr | Tier 1.5 | 0.716 | 1 | A2_pm_peripheral | 3 | 82.19 | 0 | 0 | 1 | 1 | 39564692 | 1 | chronic myelogenous leukemia | 0.5869168331059803 | ||
| P42680 | TEC | Tyrosine-protein kinase Tec | Tier 1.5 | 0.705 | 1 | A2_pm_peripheral | 1 | 85.0 | 0 | 0 | 1 | 13 | 39352470, 39329798, 36414190, 36105684, 35624657, 35462326, 35006795, 30578658, 30398689, 27548775, 26843427, 25016253, 24875764 | 1 | alopecia areata | 0.5491699656070116 | ||
| P17252 | PRKCA | Protein kinase C alpha type | Tier 1.5 | 0.704 | 1 | A2_pm_peripheral | 6 | 86.38 | 0 | 0 | 1 | 1 | 41505229 | 1 | acute myeloid leukemia | 0.547429504944985 | ||
| Q96PY5 | FMNL2 | Formin-like protein 2 | Tier 1.5 | 0.695 | 1 | A2_pm_peripheral | 1 | 76.44 | 0 | 0 | 1 | 1 | 41149482 | 1 | open-angle glaucoma | 0.5157968177633478 | ||
| P09543 | CNP | 2',3'-cyclic-nucleotide 3'-phosphodiesterase | Tier 1.5 | 0.689 | 1 | A2_pm_peripheral | 1 | 87.25 | 0 | 0 | 1 | 9 | 40034273, 38569854, 37704353, 35528922, 31171207, 30089209, 27192549, 19021295 | 1 | myopia 2, autosomal dominant | 0.49606855995054094 | ||
| P31948 | STIP1 | Stress-induced-phosphoprotein 1 | Tier 1.5 | 0.689 | 1 | A2_pm_peripheral | 8 | 89.75 | 1 | 0 | 1 | 7 | 41406518, 38012811, 34831332, 32614006, 27681499, 24654750, 24013070 | 1 | neurodegenerative disease | 0.4967711525222825 | ||
| P21980 | TGM2 | Protein-glutamine gamma-glutamyltransferase 2 | Tier 1.5 | 0.688 | 1 | A2_pm_peripheral | 17 | 92.88 | 1 | 0 | 1 | 1 | 35980938 | 1 | neurodegenerative disease | 0.49455272812698803 | ||
| P63098 | PPP3R1 | Calcineurin subunit B type 1 | Tier 1.5 | 0.673 | 1 | A2_pm_peripheral | 21 | 91.12 | 1 | 0 | 1 | 2 | 39263947 | 1 | Abnormality of the skeletal system | 0.44389060142742937 | ||
| P56470 | LGALS4 | Galectin-4 | Tier 1.5 | 0.63 | 1 | A2_pm_peripheral | 13 | 89.62 | 0 | 0 | 1 | 2 | 38811951 | 1 | neurodegenerative disease | 0.2996682866922638 | ||
| P15104 | GLUL | Glutamine synthetase | Tier 1.5 | 0.622 | 1 | A2_pm_peripheral | 12 | 97.5 | 1 | 0 | 1 | 4 | 39533430, 30085248, 21282981 | 0 | congenital brain dysgenesis due to glutamine synthetase deficiency | 0.7733687702812198 | ||
| P49862 | KLK7 | Kallikrein-7 | Tier 1.5 | 0.613 | 1 | A2_pm_peripheral | 12 | 91.56 | 0 | 0 | 1 | 1 | 30114962 | 1 | neurodegenerative disease | 0.2420324965785189 | ||
| O14640 | DVL1 | Segment polarity protein dishevelled homolog DVL-1 | Tier 1.5 | 0.611 | 1 | A2_pm_peripheral | 3 | 59.84 | 0 | 0 | 1 | 1 | 37231925 | 0 | autosomal dominant Robinow syndrome | 0.7359277384599506 | ||
| Q2Q1W2 | TRIM71 | E3 ubiquitin-protein ligase TRIM71 | Tier 1.5 | 0.578 | 1 | A2_pm_peripheral | 2 | 79.12 | 0 | 0 | 1 | 2 | 31732746 | 0 | hydrocephalus, congenital communicating, 1 | 0.6276048232841862 | ||
| P34949 | MPI | Mannose-6-phosphate isomerase | Tier 1.5 | 0.549 | 0 | A2_pm_peripheral | 0 | 96.44 | 0 | 0 | 1 | 2 | 40164941, 23933583 | 1 | MPI-congenital disorder of glycosylation | 0.8451488759060135 | ||
| Q8NF50 | DOCK8 | Dedicator of cytokinesis protein 8 | Tier 1.5 | 0.537 | 0 | A2_pm_peripheral | 0 | 74.56 | 0 | 0 | 1 | 2 | 31754797, 31029337 | 1 | combined immunodeficiency due to DOCK8 deficiency | 0.8059148942715584 | ||
| P20794 | MAK | Serine/threonine-protein kinase MAK | Tier 1.5 | 0.527 | 0 | A2_pm_peripheral | 0 | 62.12 | 0 | 0 | 1 | 3 | 38953438, 24204723, 18558676 | 1 | retinitis pigmentosa | 0.7734151865428234 | ||
| Q9Y2K6 | USP20 | Ubiquitin carboxyl-terminal hydrolase 20 | Tier 1.5 | 0.509 | 1 | A2_pm_peripheral | 1 | 72.31 | 0 | 0 | 1 | 1 | 30863411 | 0 | connective tissue neoplasm | 0.3981371748391643 | ||
| O75182 | SIN3B | Paired amphipathic helix protein Sin3b | Tier 1.5 | 0.501 | 1 | A2_pm_peripheral | 4 | 68.0 | 1 | 0 | 1 | 2 | 16914451 | 0 | syndromic intellectual disability | 0.37050380432141355 | ||
| P32298 | GRK4 | G protein-coupled receptor kinase 4 | Tier 1.5 | 0.49 | 1 | A2_pm_peripheral | 1 | 88.69 | 0 | 0 | 1 | 2 | 31555351 | 0 | Nausea and vomiting | 0.33267400228074584 | ||
| P55089 | UCN | Urocortin | Tier 1.5 | 0.469 | 1 | A2_pm_peripheral | 6 | 68.25 | 1 | 0 | 1 | 3 | 30221506, 26488412, 23248006 | 0 | neurodegenerative disease | 0.26311734927710556 | ||
| Q5VT25 | CDC42BPA | Serine/threonine-protein kinase MRCK alpha | Tier 1.5 | 0.45 | 0 | A2_pm_peripheral | 0 | 75.06 | 0 | 0 | 1 | 2 | 20564698 | 1 | neurodegenerative disease | 0.5178529990008665 | ||
| P19957 | PI3 | Elafin | Tier 1.5 | 0.446 | 1 | A2_pm_peripheral | 3 | 72.25 | 0 | 0 | 1 | 3 | 37351609, 36517803, 30087279 | 0 | Abruptio Placentae | 0.18626794135552627 | ||
| Q9NRA1 | PDGFC | Platelet-derived growth factor C | Tier 1.5 | 0.423 | 0 | A2_pm_peripheral | 0 | 75.56 | 0 | 0 | 1 | 2 | 11912250 | 1 | Abnormality of the skeletal system | 0.42503153735116955 | ||
| Q9H4F8 | SMOC1 | SPARC-related modular calcium-binding protein 1 | Tier 1.5 | 0.388 | 0 | A2_pm_peripheral | 0 | 73.31 | 0 | 0 | 1 | 1 | 36333824 | 0 | microphthalmia with limb anomalies | 0.8103774498041117 | ||
| Q9UHK6 | AMACR | Alpha-methylacyl-CoA racemase | Tier 1.5 | 0.374 | 0 | A2_pm_peripheral | 0 | 95.81 | 0 | 0 | 1 | 10 | 40271962, 35780537, 35539643, 26547498, 24994506 | 0 | Alpha-methylacyl-CoA racemase deficiency | 0.762086344446303 | ||
| O75781 | PALM | Paralemmin-1 | Tier 1.5 | 0.356 | 0 | A2_pm_peripheral | 0 | 69.0 | 0 | 0 | 1 | 12 | 41849311, 40440017, 39602515, 37268031, 37162861, 36358301, 32726320, 28237901, 26296781, 25811093, 17467026, 16849623 | 1 | Anxiety | 0.20355734593659502 | ||
| O14543 | SOCS3 | Suppressor of cytokine signaling 3 | Tier 1.5 | 0.287 | 0 | A2_pm_peripheral | 0 | 71.88 | 0 | 0 | 1 | 2 | 39571081 | 0 | neurodegenerative disease | 0.47223972419523075 | ||
| Q9P2M7 | CGN | Cingulin | Tier 1.5 | 0.251 | 0 | A2_pm_peripheral | 0 | 69.56 | 0 | 0 | 1 | 3 | 35297595, 33476120, 21342520 | 0 | Abnormality of the skeletal system | 0.3547927821140923 | ||
| Q8WW22 | DNAJA4 | DnaJ homolog subfamily A member 4 | Tier 1.5 | 0.241 | 0 | A2_pm_peripheral | 0 | 84.44 | 0 | 0 | 1 | 2 | 41935727, 33879515 | 0 | coronary atherosclerosis | 0.3210951574534216 | ||
| Q9Y5Z7 | HCFC2 | Host cell factor 2 | Tier 1.5 | 0.235 | 0 | A2_pm_peripheral | 0 | 72.88 | 0 | 0 | 1 | 24 | 41651417, 41187655, 40586934, 40410820, 40371468, 38829419, 38471488, 36836536, 36517803, 36480517, 34132569, 32981365, 32884147, 32157871, 32101978, 31985806, 31077760, 25534780, 23770039, 20967861, 20445260, 19195013, 15629041, 12177446 | 0 | neurodegenerative disease | 0.29928415571034084 | ||
| Q6XZB0 | LIPI | Lipase member I | Tier 1.5 | 0.215 | 0 | A2_pm_peripheral | 0 | 89.44 | 0 | 0 | 1 | 2 | 32981012, 27715478 | 0 | metabolic disease | 0.23399905961107478 | ||
| Q8N143 | BCL6B | B-cell CLL/lymphoma 6 member B protein | Tier 1.5 | 0.199 | 0 | A2_pm_peripheral | 0 | 54.31 | 0 | 0 | 1 | 1 | 41169059 | 0 | tympanic membrane perforation | 0.18130132303178323 | ||
| Q16206 | ENOX2 | Ecto-NOX disulfide-thiol exchanger 2 | Tier 1.5 | 0.167 | 0 | A2_pm_peripheral | 0 | 77.06 | 0 | 0 | 1 | 2 | 37504074 | 0 | chronic myelogenous leukemia | 0.0726224414455439 | ||
| O77932 | DXO | Decapping and exoribonuclease protein | Tier 1.5 | 0.161 | 0 | A2_pm_peripheral | 0 | 92.69 | 0 | 0 | 1 | 2 | 27432610 | 0 | breast cancer | 0.05174117965585824 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;